Key Factor Supporting Kinase Inhibitors Market Development in 2025: Rise In Cases Of Autoimmune Diseases To Expand Kinase Inhibitors

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Kinase Inhibitors Market Size By 2025?
The market for kinase inhibitors has experienced substantial growth in the past few years. The market value is expected to rise from $62.75 billion in 2024 to $67.57 billion in 2025 with a compound annual growth rate (CAGR) of 7.7%. The increase during the historic phase can be attributed to various factors such as the burgeoning prevalence of cancer, developments in targeted therapy, increasing health care spending, approval of new kinase inhibitors, and the escalating application of personalized medicine.

How Big Is the Kinase Inhibitors Market Size Expected to Grow by 2029?
In the coming years, the kinase inhibitors market is projected to experience robust growth, rising to a valuation of $89.57 billion by 2029, with a compound annual growth rate (CAGR) of 7.3%. This growth for the forecasted period is due to factors such as ongoing research and development efforts, the arrival of innovative kinase inhibitors, the widening of applications beyond just oncology, increased biotech investment, and a heightened awareness of precision medicine. The forecast period will also witness trends such as the growth of precision oncology treatments, the creation of combination therapies, a heightened focus on rare and difficult-to-treat cancers, advancements in drug development driven by biomarkers, and an increase in the uptake of next-generation sequencing technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Which Key Market Drivers Powering Kinase Inhibitors Market Expansion and Growth?
The escalating occurrence of autoimmune disorders is projected to spur the expansion of the kinase inhibitors market. These disorders involve an abnormal immune response that erroneously harms healthy cells, tissues, and organs. Factors contributing to the surge in autoimmune diseases include lifestyle and dietary changes, environmental pollution, genetic factors, stress, microbial imbalances, and the rising incidence of chronic diseases such as diabetes and obesity. Kinase inhibitors offer treatment advantages for such diseases by altering the immune system, decreasing inflammation, and relieving symptoms such as psoriatic and rheumatoid arthritis. For example, in December 2022, the National Psoriasis Foundation, a US-based non-profit organization serving people with Psoriasis and psoriatic arthritis, reported Psoriasis affecting more than 8 million in America and 125 million globally, equating to 2 to 3% of the population. Further, the Centers for Disease Control and Prevention, a US national public health agency, reported in September 2022 that 28.7 million people of all ages, or 8.7% of the US population, were diagnosed with Diabetes and out of these, 5.7% of all US individuals with confirmed Diabetes-or 1.6 million people aged 20 and above-required insulin due to type 1 diabetes. Hence, the escalating occurrence of autoimmune disorders is fuelling the kinase inhibitors market growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15841&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Kinase Inhibitors Market?
Firms that are major players in the kinase inhibitors market are advancing their research and development to create selective tyrosine kinase 2 (TYK2) inhibitors. This innovation aims to fulfill the unattended necessities in combating auto-immune and inflammatory diseases. Selective tyrosine kinase 2 (TYK2) inhibitors play a vital role in cancer treatment by adjusting immune responses and reducing inflammation, which in turn boosts the individual's capability to find and eradicate cancer cells while building an unfavorable environment for tumor expansion. In an example from September 2022, the U.S. Food and Drug Administration (FDA) granted approval for Sotyktu (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor manufactured by Bristol-Myers Squibb Company, a leading pharmaceutical firm in the US. This medication is intended for the treatment of adult patients with moderate-to-severe plaque psoriasis that require systemic or phototherapy treatment. The initiation of Sotyktu is a significant stride forward in treating plaque psoriasis, providing a novel alternative for patients who might not sufficiently respond to currently available treatments.

What Are the Emerging Segments in the Kinase Inhibitors Market?
The kinase inhibitors market covered in this report is segmented -

1) By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Application: Oncology, Inflammatory Diseases
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, HER2 Inhibitors, BCR-ABL Inhibitors, Other Tyrosine Kinase Inhibitors
2) By Multikinase Inhibitors: VEGFR Inhibitors, PDGFR Inhibitors, FGFR Inhibitors, Other Multikinase Inhibitors
3) By MTOR Kinase Inhibitors: Everolimus, Temsirolimus, Other MTOR Kinase Inhibitors
4) By Other Types: JAK Inhibitors, ROCK Inhibitors, CDK Inhibitors, Other Kinase Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15841&type=smp

Who Are the Global Leaders in the Kinase Inhibitors Market?
Major companies operating in the kinase inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Dr. Reddy's Laboratories Ltd., Endo International Inc., Amneal Pharmaceuticals LLC, Lupin Limited, Exelixis Inc., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hutchison China MediTech Limited, Akorn Incorporated, Ocular Therapeutix Inc., Sierra Oncology Inc

Which are the Top Profitable Regional Markets for the Kinase Inhibitors Industry?
Asia-Pacific was the largest region in the kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15841

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.